Group
Biotech
11 themes97 tickers
10D rank#9of 142 groups
Dive into Biotech, where we explore everything from established pharma giants and cutting-edge GLP-1 therapies to revolutionary oncology, genetic medicine, and AI-driven drug discovery. Understand what's going on in health innovation!
Biotech '24: GLP1+49.51%9.1%
Biotech '24: Oncology+44.56%9.1%
Biotech '24: Pharma/Therapeutics+39.91%9.1%
Biotech '25: Commercial / Late Stage+14.22%9.1%
Biotech '25: Neurology, CNS & Rare Disorders+48.45%9.1%
Biotech '25: Oncology & Immunotherapy+98.43%9.1%
Biotech '25: RNA-Based/Genetic Medicine+188.75%9.1%
Biotech '26: AI Driven Drug Discovery+101.25%9.1%
Biotech '26: Established Pharma+42.29%9.1%
Biotech '26: Psychedelic Drugs+97.86%9.1%
Biotech '26: Scalable Oncology Drugs+67.59%9.1%
As of Aug 24, 2026, 4:48 AM ET
Themes in this group
Build 20260824T084825
| Biotech '26: Psychedelic Drugs | 11 | $962.1M | $10.58B | +1.13% | +11.02% | +19.68% | +21.96% | +88.24% | +97.86% | +50.76% | -6.78% | +41.35% | +40.11% | +85.37% | +144.88% | +5.81% | -1.00% |
| Biotech '25: RNA-Based/Genetic Medicine | 7 | $5.43B | $38.03B | +1.16% | +6.65% | +24.83% | +25.32% | +82.40% | +188.75% | +76.41% | +132.65% | +33.70% | +44.50% | +62.91% | +356.30% | +1.98% | +15.81% |
| Biotech '26: AI Driven Drug Discovery | 18 | $93.88B | $1.69T | +1.38% | +5.65% | +21.66% | +19.08% | +68.05% | +101.25% | +88.68% | +45.37% | +36.98% | +63.95% | +57.27% | +120.00% | +5.49% | +7.84% |
| Biotech '26: Scalable Oncology Drugs | 12 | $19.54B | $234.43B | +1.35% | +5.54% | +8.27% | +13.56% | +21.81% | +67.59% | +63.37% | +115.23% | +14.71% | +16.58% | +23.21% | +84.82% | +3.28% | +3.65% |
| Biotech '24: Oncology | 8 | $3.72B | $29.73B | -0.65% | +5.54% | +16.40% | +21.82% | +41.82% | +44.56% | +55.98% | -7.61% | +27.16% | +20.80% | +23.37% | +101.98% | +7.42% | +12.48% |
| Biotech '25: Oncology & Immunotherapy | 12 | $6.45B | $77.45B | +1.26% | +5.28% | +11.30% | +13.79% | +38.47% | +98.43% | +105.86% | +172.41% | +18.39% | +28.76% | +35.92% | +141.00% | +3.00% | +7.03% |
| Biotech '26: Established Pharma | 10 | $206.12B | $2.06T | +1.53% | +5.12% | +13.78% | +11.42% | +23.79% | +42.29% | +33.83% | +67.76% | +22.55% | +24.47% | +15.98% | +48.99% | +3.03% | +11.05% |
| Biotech '25: Neurology, CNS & Rare Disorders | 7 | $1.34B | $9.38B | +1.84% | +3.59% | +2.11% | +4.23% | +12.61% | +48.45% | +53.89% | +263.29% | +2.29% | +9.97% | +8.04% | +102.34% | -2.43% | +7.32% |
| Biotech '24: GLP1 | 4 | $8.65B | $34.62B | +0.52% | +1.27% | +4.69% | +6.32% | +2.42% | +49.51% | +2.99% | +471.58% | +15.52% | +16.99% | +7.72% | +59.89% | +3.36% | +1.66% |
| Biotech '24: Pharma/Therapeutics | 13 | $4.15B | $53.93B | +0.77% | -0.36% | +9.86% | +10.93% | +12.03% | +39.91% | +55.22% | +135.66% | +10.39% | +23.70% | +9.48% | +87.46% | +9.88% | +2.69% |
| Biotech '25: Commercial / Late Stage | 5 | $5.65B | $28.26B | +0.08% | -1.19% | +1.48% | +6.89% | -6.25% | +14.22% | +28.99% | +59.63% | -2.31% | +10.72% | +1.32% | +26.75% | +9.70% | +1.06% |
Default: 10D ↓ · Click headers to sort · Shift+click secondary